Advanced Solid Tumor
Why trials studying Advanced Solid Tumor stopped, in this sample of ClinicalTrials.gov.
25 stopped trials with a clear reason; 92% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 22 | 88% |
| futility | 1 | 4% |
| slow accrual | 1 | 4% |
| safety | 1 | 4% |
Trials
- A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
NCT06682806 · TERMINATED · funding business
“Sponsor decision” - M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
NCT06509906 · TERMINATED · funding business
“Sponsor Decision” - Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT06130254 · TERMINATED · funding business
“Sponsor discontinued the trial” - Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
NCT05756907 · TERMINATED · futility
“Failed to meet efficacy endpoint criteria, despite lack of safety concerns” - BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
NCT05935098 · TERMINATED · safety
“This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.” - A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
NCT05821777 · TERMINATED · funding business
“Sponsor terminated the study due to non-safety reasons. Based on the data and the current competitive landscape, Sponsor made the decision to close the study.” - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NCT05714553 · TERMINATED · funding business
“The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.” - Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
NCT05621525 · TERMINATED · funding business
“Business reason” - TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
NCT05525455 · TERMINATED · funding business
“Company operational decision. Decision to stop study is not due to safety or efficacy concerns.” - A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
NCT05346484 · TERMINATED · funding business
“Portfolio prioritization” - Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
NCT05126433 · TERMINATED · funding business
“Termination of this study was a business decision made during portfolio review.” - A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
NCT05148533 · TERMINATED · funding business
“Company Development strategy adjustment” - Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
NCT05109442 · TERMINATED · funding business
“The trial was prematurely discontinued due to the financial situation of the sponsor and not for safety or efficacy reasons.” - Study of LM-102 in Patients With Advance Solid Tumors
NCT05008445 · TERMINATED · funding business
“company adjusted strategy” - A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
NCT05036291 · TERMINATED · funding business
“Development change” - Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
NCT04892017 · TERMINATED · funding business
“Trial terminated due to business decision, not based on any safety or efficacy concerns.” - A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
NCT04799054 · TERMINATED · funding business
“The Sponsor made the decision to close enrollment to prioritize our efforts on TransCon IL-2 ß/g.” - Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
NCT04488003 · TERMINATED · slow accrual
“Enrollment challenges” - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT04682431 · TERMINATED · funding business
“Sponsor business decision.” - A Study of PY314 in Subjects With Advanced Solid Tumors
NCT04691375 · TERMINATED · funding business
“Sponsor business decision.” - A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT04442126 · TERMINATED · funding business
“A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.” - Study to Assess AFM24 in Advanced Solid Cancers
NCT04259450 · TERMINATED · funding business
“Enrollment into expansion cohorts in Phase 2 part was terminated due to sponsor decision” - A Study of CS3002 in Subjects With Advanced Solid Tumors
NCT04162301 · TERMINATED · funding business
“The study has been stopped for strategic and business reasons.” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
NCT04106167 · TERMINATED · funding business
“This study was terminated by the Sponsor.” - Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
NCT02168725 · TERMINATED · funding business
“The study was placed on hold by the FDA due to manufacturing issues and was not restarted.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.